Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune® HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC)

EP. 1: Introduction and Incidence of HPV-Positive Head and Neck Cancer

December 23rd 2024

A panelist discusses the incidence of HPV+ HNSCC, and how has it changed in recent years.

EP. 2: Understanding HPV-Positive HNSCC: Disease Presentation and Risk Factors

January 20th 2025

Panelists discuss how, HPV-positive head and neck squamous cell carcinoma (HPV+ HNSCC) typically presents differently from HPV-negative cases. Patients often present with smaller primary tumors but more advanced nodal disease, commonly with cystic lymph node metastases in the neck. The most frequent site is the oropharynx, particularly the tonsils and base of tongue.

EP. 3: Navigating Treatment for HPV-Positive HNSCC Patients

January 20th 2025

Panelists discuss how, HPV+ head and neck cancer treatment typically follows NCCN guidelines: primary therapy includes surgery and/or chemoradiation based on staging. Immunotherapy like pembrolizumab is increasingly used, especially for recurrent/metastatic disease. Prognosis is generally better than HPV- cases.